Placebo Effect or Just Bad News? Omeros Down On OMS721 IgA Nephropathy Data

 
• By Sten Stovall
  
Kidney
Omeros Jarred Investors With Mixed Results In Its Phase II IgAN Study • Source: Shutterstock

More from Clinical Trials

More from R&D